V8 Peptides — Engineered Performance
Research Library
CJC-1295 DAC Pharmacokinetics: Half-Life Explained
CJC-1295 DACPreclinical

CJC-1295 DAC Pharmacokinetics: Half-Life Explained

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

What do "half-life" and "bioavailability" mean for CJC-1295 with DAC in preclinical work? Terminal half-life is the time for plasma concentration to fall by half after pseudo-equilibrium, not the time to eliminate half a dose, and for a long-lived conjugate it can reflect absorption or carrier turnover rather than elimination of free peptide. The published rat work reported that CJC-1295 was present in plasma beyond 72 hours and bound to the albumin band for over 24 hours, versus a 6.8-minute in vivo half-life for intact native GHRH(1-44). Bioavailability is the fraction of a non-vascular dose reaching the circulation; the cited abstracts do not report it for CJC-1295. This article defines the terms and the measurement traps. For laboratory research use only.

Pharmacokinetic words are used loosely in peptide writing. "Half-life", "duration" and "persistence" are regarded as synonyms, and "bioavailability" is sometimes used to mean "it works". For a conjugate that rides on albumin the loose usage causes real errors, because the number reported depends on what was measured: free peptide, albumin-bound peptide, immunoreactivity or biological activity. This article defines the terms the way pharmacokinetic reviews do, applies them to the preclinical CJC-1295 literature, and shows where the published abstracts stop. It is a research explainer only; not for human or animal consumption.

Definitions that matter

Terminal plasma half-life is the time required to divide the plasma concentration by two after reaching pseudo-equilibrium, and not the time required to eliminate half the administered dose. When absorption is not limiting, half-life is a hybrid parameter controlled by plasma clearance and extent of distribution; when absorption is limiting, the terminal half-life reflects the rate and extent of absorption rather than elimination, a situation called flip-flop pharmacokinetics (Toutain and Bousquet-Mélou, 2004a). Bioavailability, in the same authors’ words, is the proportion of a drug given by any non-vascular route that gains access to the systemic circulation, and its measurement can be absolute (against intravenous administration) or relative (against another formulation) (Toutain and Bousquet-Mélou, 2004b).

TermWhat it meansCommon misuse
Terminal half-lifeTime for plasma concentration to halve in the terminal phaseExposed as the time to remove half the dose
ClearanceVolume of plasma cleared per unit timeConfused with half-life
Volume of distributionApparent space the drug occupiesIgnored when comparing half-lives
BioavailabilityFraction of a non-vascular dose that reaches the circulationUsed to mean potency or effect
Duration of actionHow long a biological effect persistsAssumed equal to plasma half-life
Flip-flop kineticsAbsorption slower than elimination, so terminal slope reflects absorptionRarely tested

What native GHRH looked like in plasma

The reference point for the whole conjugate story is the native hormone. Frohman and colleagues (1986) found that when human GHRH(1-44)-amide was incubated with human plasma, total immunoreactivity had a half-life of 63 minutes by radioimmunoassay, but HPLC showed a faster disappearance of the intact peptide, with a half-life of 17 minutes, accompanied by appearance of GHRH(3-44)-amide with less than one-thousandth of the biological activity. After intravenous administration in normal subjects the half-life of intact GHRH(1-44)-amide by HPLC was 6.8 minutes. That paper is a reminder that the method matters: radioimmunoassay saw a longer half-life than HPLC because the inactive metabolite was still immunoreactive. A pharmacokinetic number without its assay is incomplete.

What the CJC-1295 rat paper measured

In the 2005 report, the best of three maleimido-hGRF(1-29) conjugates, CJC-1295, produced a 4-fold increase in GH area under the curve over a 2-hour period compared with hGRF(1-29) after subcutaneous administration to normal male rats, and was found to be present in plasma beyond 72 hours. A Western blot of plasma from an rat given CJC-1295 showed a CJC-1295 immunoreactive species on the band corresponding to serum albumin, appearing after 15 minutes and remaining in circulation beyond 24 hours (Jetté and colleagues, 2005). Three points follow from the way these results are expressed. The 72-hour figure is a detection claim, meaning the compound could still be detected, not a calculated half-life. The albumin-band observation shows association with albumin, not the fraction that remained bioactive. And the area-under-the-curve comparison concerns GH secretion over 2 hours, a pharmacodynamic measure, not a plasma concentration profile of the peptide itself.

Reported resultQuantity typeWhat it supportsWhat it does not support
Detectable in plasma beyond 72 h (rats)Detection timeLong persistence of an immunoreactive speciesA specific terminal half-life value
Albumin-band species from 15 min to beyond 24 hWestern blot associationCovalent or stable albumin association in vivoThe bioactive fraction over time
4-fold GH AUC over 2 h vs hGRF(1-29)Pharmacodynamic responseGreater short-term GH releaseBioavailability or clearance
Normal growth at once-daily interval in knockout miceEfficacy at a scheduleFunctional persistence on a daily timescalePlasma concentration at the trough

Why a long half-life is not one number

A peptide that is covalently bound to albumin has at least three populations: free peptide, peptide-albumin conjugate and metabolized fragments. Each has its own clearance. The conjugate’s fate is tied to albumin’s, and albumin turnover is influenced by the neonatal Fc receptor, which binds albumin and prolongs its lifespan; the half-life of albumin in FcRn-deficient mice was less than half that of wild-type mice (Chaudhury and colleagues, 2003). Kratz (2008) described binding a peptide covalently or physically to albumin as a way to enhance its stability and half-life. The net result is that terminal half-life for the conjugate is largely a property of albumin kinetics and of the stability of the linkage, with species dependence: albumin half-life differs between mouse, rat and larger animals, so a figure from one species does not carry to another. The chemistry of the linkage adds its own variable, discussed in the DAC versus no-DAC comparison.

Bioavailability: what to measure, and why not to assume it

Absolute bioavailability requires an intravenous reference. For a subcutaneous peptide the practical measures are the area under the concentration-time curve after each route, corrected for dose, and the maximal concentration and time to maximum, which Toutain and Bousquet-Mélou caution can be difficult to use for rate of absorption (2004b). For an albumin-binding conjugate, a further complication arises because the quantity that matters can be defined three ways: total immunoreactive peptide, albumin-bound peptide or biologically active peptide. A study reporting "bioavailability" should specify which. None of the abstracts cited in this article reports a bioavailability value for CJC-1295, so any specific figure encountered elsewhere should be traced to its original study and assay before it is repeated.

Assay design for a pharmacokinetic study

  1. Choose the analyte. Total peptide by immunoassay, albumin-bound species by blotting or mass spectrometry, and bioactivity by a cell-based cAMP or GH-release assay answer different questions.
  2. Validate against metabolites. The 1986 example shows that an immunoassay can read inactive metabolites as active compound.
  3. Sample densely at early and late times. A multi-phase profile cannot be fitted from two time points.
  4. Include a reference route. Intravenous administration allows clearance and volume estimates and absolute bioavailability.
  5. State the species, sex, age and fasting status. Albumin levels and turnover vary with all of these.
  6. Record the stock history. Solution age and storage, since a degraded stock lowers the true administered amount; see how long reconstituted peptides last.

How this connects to the product catalog

V8 lists the CJC-1295 (No DAC) reagent, which lacks the albumin linker and is the short-persistence comparator in these designs. The research guide for that form is the CJC-1295 (No DAC) research guide, and the DAC form is covered in the DAC research overview. Pharmacokinetic comparisons are only as sound as the stock concentration, which comes from the vial mass and solvent volume (c = m ÷ V); the reconstitution calculator and how to read a COA support that step. The catalog lists the remaining reagents.

Worked example of the half-life arithmetic

For a single-compartment profile, the terminal rate constant k is the negative slope of the natural log of concentration against time, and half-life is ln 2 ÷ k, or 0.693 ÷ k. If concentration fell by half every 17 minutes, k would be 0.693 ÷ 17 = 0.041 per minute. The same arithmetic applies to any compound, but its meaning depends on the compartment model and on whether the analyte is free or bound. For a conjugate, a log-linear terminal phase suggests a single dominant elimination process, while a curve that bends suggests more than one population, for example free peptide clearing quickly and albumin-bound peptide clearing slowly. Fitting a single exponential to a bent curve gives a half-life that is an average of two processes and describes neither. This is why a minimum of three to four points in the terminal phase is normally recommended before any half-life is reported, and why the assay’s lower limit of quantification must be stated, since a profile that falls below it is truncated and can bias the estimate.

Limits of this article

The 2005 and 2006 reports are the principal open-access-style descriptions of the preclinical persistence of this conjugate, and they come from the developing sponsor and collaborating academic groups. They are rodent studies, and they do not provide a full compartmental analysis in the abstracts cited here. No statement in this article applies outside the laboratory.

For laboratory research use only.

Frequently asked questions

What is terminal half-life?

The time required to divide plasma concentration by two after pseudo-equilibrium is reached. It is not the time needed to eliminate half the administered dose.

What is flip-flop pharmacokinetics?

A situation in which absorption is slower than elimination, so the terminal half-life reflects absorption rate and extent, not elimination.

What is bioavailability?

The proportion of a drug given by a non-vascular route that gains access to the systemic circulation. It can be absolute, against intravenous, or relative, against another formulation.

What half-life was reported for native GHRH?

In plasma in vitro the intact peptide had a half-life of 17 minutes by HPLC, and in vivo after intravenous administration it was 6.8 minutes in normal subjects (Frohman and colleagues, 1986).

What did the 2005 rat study report about persistence?

CJC-1295 was present in plasma beyond 72 hours, and an albumin-band immunoreactive species was seen from 15 minutes to beyond 24 hours.

Is the 72-hour figure a half-life?

No. It is a detection time. A half-life would need a fitted concentration-time profile.

Do the cited abstracts report a bioavailability value for CJC-1295?

No. Any figure encountered elsewhere should be traced to the original study and assay.

Why does the assay method matter?

Radioimmunoassay read a longer half-life than HPLC for native GHRH because the inactive metabolite was still immunoreactive.

Why can't a mouse half-life be applied to other species?

Albumin turnover differs between species and depends on FcRn, so a conjugate’s persistence is species-specific.

Where can I find the stock concentration formula?

Concentration equals vial mass divided by solvent volume. The reconstitution calculator and its guide show the arithmetic.

Related reading: CJC-1295 DAC Storage, Stock Math and Study Parameters, CJC-1295 DAC Safety Profile: Preclinical Tolerability, CJC-1295 DAC vs No DAC: Which Form Fits the Assay?.

References

  1. Toutain PL, Bousquet-Mélou A. Plasma terminal half-life. J Vet Pharmacol Ther. 2004;27(6):427-439. doi:10.1111/j.1365-2885.2004.00600.x
  2. Toutain PL, Bousquet-Mélou A. Bioavailability and its assessment. J Vet Pharmacol Ther. 2004;27(6):455-466. doi:10.1111/j.1365-2885.2004.00604.x
  3. Frohman LA, Downs TR, Williams TC, Heimer EP, Pan YC, Felix AM. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus. J Clin Invest. 1986;78(4):906-913. doi:10.1172/JCI112679
  4. Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286
  5. Chaudhury C, Mehnaz S, Robinson JM, et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med. 2003;197(3):315-322. doi:10.1084/jem.20021829
  6. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release. 2008;132(3):171-183. doi:10.1016/j.jconrel.2008.05.010
  7. Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.